For HGD the risk of developing Oesophageal cancer is >10% per patient year.

Oesophageal cancer has the highest incidence in the UK, Netherlands and Ireland.

For HGD the risk of developing Oesophageal cancer is >10% per patient year.

Increase in population mortality for oesophageal cancer is predicted to increase over the next 10 years.

Cancers of the oesophagus & stomach are the fifth most common in the UK & affect around 16,000 people each year.

Oesophageal cancer is the sixth most common cause of cancer death in the UK.

Only 15% of oesophageal cancer (OGC) patients survive 5 years after diagnosis.

28.9% of HGD patients remain on surveillance only. There is a significant variation in patient access to treatment across the NHS.

3% of all cancer deaths in women.

6% of all cancer deaths in men.

3% of all cancer deaths in men.

Oesophageal & Gastric Cancer account for:

28.9% of HGD patients remain on surveillance only. There is a significant variation in patient access to treatment across the NHS.

ECONOMICS

Barrx™ RFA is a cost-effective option for patients with HGD in the UK, with an ICER of £1,272.

RFA dominated oesophagectomy, generating 0.4 additional QALYs with a cost saving of £1902.

Only 15% of oesophageal cancer (OGC) patients survive 5 years after diagnosis.

For HGD the risk of developing Oesophageal cancer is >10% per patient year.

Increase in population mortality for oesophageal cancer is predicted to increase over the next 10 years.

Cancers of the oesophagus & stomach are the fifth most common in the UK & affect around 16,000 people each year.

Oesophageal cancer is the sixth most common cause of cancer death in the UK.

ECONOMICS

Barrx™ RFA is a cost-effective option for patients with HGD in the UK, with an ICER of £1,272.

RFA dominated oesophagectomy, generating 0.4 additional QALYs with a cost saving of £1902.